Status: Recruiting
Study of ALK-001 on the Progression of Stargardt Disease
This study evaluates the efficacy and safety of investigational study drug ALK-001 in participants 8 to 45 years of age, inclusive, with symptoms and signs of autosomal recessive Stargardt disease (STGD)
Participants needed: 230
Trial details
Phase: Phase 3Age: 8-45Biological sex: AllType: InterventionalSponsor: Alkeus Pharmaceuticals, Inc.Updated: Jul 2, 2026Locations: 5
Eligibility criteria
Male or female, 8 to 45 years of age (inclusive) on the day of screening. [+4]
Has taken disallowed items (supplements containing vitamin A or beta-carotene, l... [+4]